Abstracts tagged "IL-6"

Abstract Number: 784 • 2014 ACR/ARHP Annual Meeting
Novel Inhibitory Effects of Mast Cells in Aortitis Involves Aortic Expression of Suppressor of Cytokine Signaling-1
Jason Springer¹, Vineesh Raveendran², Donald Smith³, Mehrdad Maz⁴ and Kottarappat Dileepan², ¹Department of Rheumatology, University of Kansas Medical Center, Kansas City, KS, ²Department of Medicine, University of Kansas Medical Center, Kansas City, KS, ³University of Kansas Medical Center, Kansas City, KS, ⁴Division of Rheumatology, University of Kansas Medical Center, Kansas City, KS
Background/Purpose Early in the pathogenesis of Giant Cell Arteritis (GCA) dendritic cells interact with T cells of both Th1 and Th17 origin. IL-6; released by…
Abstract Number: 2824 • 2014 ACR/ARHP Annual Meeting
A Profile of the Efficacy of Sarilumab Plus Methotrexate in Rheumatoid Arthritis Patients: Results of a 52-Week, Phase 3, Randomized, Double-Blind, Placebo-Controlled, International Study
Arthur Kavanaugh¹, Dennis L. Decktor², Chunpeng Fan³, Janet van Adelsberg², Renata Martincova⁴ and Mark C. Genovese⁵, ¹University of California San Diego, La Jolla, CA, ²Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ³Biostatistics, Sanofi, Bridgewater, NJ, ⁴Sanofi Czech Republic, Prague, Czech Republic, ⁵Stanford University Medical Center, Palo Alto, CA
Background/Purpose Interleukin-6 (IL-6) regulates a diverse array of activities that may underlie systemic and local symptoms of rheumatoid arthritis (RA). The efficacy of sarilumab, a…
Abstract Number: 497 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety Study of a Sequential Therapy of Tocilizumab and, If Initially Inadequately Responded to Tocilizumab, Followed By Rituximab in Patients with Rheumatoid Arthritis and Inadequate Response to Traditional Disease Modifying Anti-Rheumatic Drugs
Thomas Dörner¹, Hans-Peter Tony², Gerd Burmester¹, Hendrik Schulze-Koops³, Jörg Kaufmann⁴, Peter Kästner⁵, Herbert Kellner⁶, Reiner Kurthen⁷, Sylke Wagner⁸, Marvin A. Peters⁹ and Christoph Iking-Konert¹⁰, ¹Charité - Universitätsmedizin Berlin, Berlin, Germany, ²University Clinic Wuerzburg, Wuerzburg, Germany, ³University Clinic Munich, Munich, Germany, ⁴Rheumatology Practice, Ludwigsfelde, Germany, ⁵MVZ Out-patient Rheumatogy Unit Erfurt, Erfurt, Germany, ⁶Specialist Practice for Rheumatology and Gastroenterology, Munich, Germany, ⁷Rheumatology Practice, Aachen, Germany, ⁸Practice for Internal Medicine specialized in Rheumatology, Halle, Germany, ⁹Roche Pharma AG, Grenzach-Wyhlen, Germany, ¹⁰University Clinic Hamburg-Eppendorf, Hamburg, Germany
Background/Purpose: The MIRAI study evaluated a sequential exposure to 2 defined biologics under rigorous study conditions within a homogeneous population of biological naïve patients (pts)…
Abstract Number: 2795 • 2014 ACR/ARHP Annual Meeting
Blockade of IL-6R Signaling by Sarilumab Suppressed Circulating Markers of Bone Resorption and Synovial Damage in Rheumatoid Arthritis Patients from a Phase 3, Randomized, Double-Blind, Placebo-Controlled, International Study
Anita Boyapati¹, Jérôme Msihid², Emmanuelle Cousin³, Ling Cai⁴, Janet van Adelsberg¹, Jennifer D Hamilton¹, Neil Graham⁵, Tanya Momtahen⁶ and Stefano Fiore⁷, ¹Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ²Sanofi R&D, France, Chilly-Mazarin, NJ, France, ³Sanofi R&D, France, Chilly-Mazarin, France, ⁴Sanofi R&D, China, Beijing, China, ⁵Program Direction, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁶Sanofi, Bridgewater, NJ, ⁷Distinct Project Unit, Sanofi, Bridgewater, NJ
Background/Purpose Rheumatoid arthritis (RA) patients develop bone and joint damage due to chronic inflammation mediated by critical cytokines, eg, IL-6. Pre-clinical studies have implicated IL-6…
Abstract Number: 332 • 2014 ACR/ARHP Annual Meeting
Improvement of the Stability of RNA Aptamers Against Interleukin-17A
Natsuki Otaki¹, Asako Sasaki¹, Shinsuke Hiramoto¹, Masakazu Nagamine¹, Shigeyuki Mori¹, Tomoyoshi Kayo¹, Kuniyoshi Hota¹, Masayuki Takahashi¹, Kazuhiko Haruta² and Yoshikazu Nakamura^3,4, ¹Zenyaku Kogyo Co., Ltd., Tokyo, Japan, ²2-33-7 Oizumi, Nerima, Zenyaku Kogyo Co., Ltd., Tokyo, Japan, ³Division of RNA Medical Science, The Institute of Medical Science, The University Of Tokyo, Tokyo, Japan, ⁴RIBOMIC Inc., Tokyo, Japan
Background/Purpose Aptamers are RNA or DNA oligonucleotides selected for their capacity to specifically bind and inhibit the function of a target protein. The effect is…
Abstract Number: 2508 • 2014 ACR/ARHP Annual Meeting
Tocilizumab Serum Trough Levels and Its Relationship with Disease Activity and Drug Dosage in Rheumatoid Arthritis Patients
Virginia Ruiz-Esquide¹, Azucena Gonzalez-Navarro², Jordi Yagüe³, Jose Inciarte-Mundo¹, M. Victoria Hernández¹, Julio Ramirez¹, Sonia Cabrera-Villalba¹, Juan D. Cañete¹ and Raimon Sanmarti¹, ¹Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ²Immunology Department, Hospital Clinic of Barcelona, Barcelona, Spain, ³Immunology Department, Hospital Clinic Barcelona, Barcelona, Spain
Background/Purpose Tocilizumab (TCZ) is a humanized monoclonal antibody against interleukin-6 receptor used for the treatment of active rheumatoid arthritis (RA). The response to this treatment…
Abstract Number: 30 • 2014 ACR/ARHP Annual Meeting
Inhibiting Autocrine Interleukin-6 (IL-6) Trans-Signalling in Human CD14^+VE Monocultures Reduces Osteoclast Differentiation
Lauren A. Jordan¹, Fraser L. Collins², Simon A. Jones¹, Ernest H. Choy³, Ann K. Harvey¹ and Anwen S. Williams¹, ¹Cardiff University, Institute of Infection and Immunity, School of Medicine, Cardiff, United Kingdom, ²Michigan State University, Department of Physiology, East Lansing, MI, ³Section of Rheumatology, Cardiff University, Institute of Infection and Immunity, School of Medicine, Cardiff, United Kingdom
Background/Purpose: Interleukin-6 (IL-6) and the inflammatory CC-chemokine CCL3 are highly expressed in rheumatoid arthritis, juvenile idiopathic arthritis and multiple myeloma. While these mediators contribute to…
Abstract Number: 2455 • 2014 ACR/ARHP Annual Meeting
IL-6 Proximal Promoter SNP rs18000795 Genotype Strongly Correlates with Synovial Fibroblast IL-6 Expression
Erika Noss¹, Sook Kyung Chang², Gerald Watts² and Michael Brenner², ¹Divison of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose Interleukin (IL)-6 is an important driver of rheumatoid arthritis (RA) pathology, and synovial fibroblasts are a major source of IL-6 in the RA synovium. …
Abstract Number: 2464 • 2014 ACR/ARHP Annual Meeting
Anti-Arthritic Effect of Tubastatin A, a Novel Histone Deacetylases-6 Inhibitor, Is Mediated By Stabilization of IkB Via Suppression of Ubiquitin-Proteasome Pathway
Eun Chung Hong¹, Hemin Jeong², Jiwon Hwang², Eun-Kyung Bae¹, Hyungjin Kim², Joong Kyong Ahn³, Hoon-Suk Cha², Eun-mi Koh⁴ and Jaejoon Lee⁴, ¹Samsung Biomedical Research Institute, Seoul, South Korea, ²Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ³Sungkyunkwan univ. school of medicine, Seoul, South Korea, ⁴Division of Rheumatology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
Background/Purpose: Histone deacetylase-6 (HDAC-6) functions as a non-epigenetic deacetylase for non-histone substrates and regulates microtubule-mediates processes such as cell migration, cell cycle arrest, and angiogenesis.…
Abstract Number: 2345 • 2014 ACR/ARHP Annual Meeting
Anti-IL-6 Receptor Antibody Prevents Deterioration in Bone Structure in a Mouse Model of Collagen-Induced Arthritis
Hiroto Yoshida, Mika Yagoto, Miho Suzuki, Keisuke Tanaka, Misato Hashizume and Yoshihiro Matsumoto, Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan
Background/Purpose: Rheumatoid arthritis (RA) is a disease that typically induces secondary osteoporosis, which increases the risk of bone fractures and, consequently, mortality. Bone fracture is…
Abstract Number: 1956 • 2014 ACR/ARHP Annual Meeting
Increased IL-6 Production By Effector B Cells in Giant Cell Arteritis and Polymyalgia Rheumatica
Kornelis S.M. van der Geest¹, Wayel H. Abdulahad², Gerda Horst³, Abraham Rutgers², Annemieke M.H. Boots⁴ and Elisabeth Brouwer⁵, ¹Dept. of Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ²Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ³University Medical Center Groningen, Groningen, Netherlands, ⁴Dept. of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁵Hanzeplein 1, UMCG, Groningen, Netherlands
Background/Purpose: The role of B cells in auto-immunity may extend beyond the production of auto-antibodies. B cells can influence T cell responses via antigen presentation…
Abstract Number: 1906 • 2014 ACR/ARHP Annual Meeting
IL-6 Blockade Reduces Circulating N-Terminal Pro-Brain Natriuretic Peptide Levels in Patients with Active Rheumatoid Arthritis
Atsuma Nishiwaki¹, Hitomi Kobayashi², Yasuyuki Kobayashi³, Isamu Yokoe¹, Noboru Kitamura², Hidetake Shiraiwa¹, Takamasa Nozaki¹, Hirotake Inomata², Natsumi Ikumi⁴, Kaita Sugiyama¹, Yousuke Nagasawa¹ and Masami Takei⁵, ¹Nihon University School of Medicine, Tokyo, Japan, ²Division of Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, ³Radiology, St.Marianna University School of Medicine, Kawasaki, Japan, ⁴Division of Heamatology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, ⁵Dept of Med Rheumatology, Nihon University School of Medicine, Itabashi Tokyo, Japan
Background/Purpose Patients with rheumatoid arthritis (RA) have a 1.5–2.0 fold higher risk of developing congestive heart failure (CHF) than the general population. Small increases in…
Abstract Number: 1714 • 2014 ACR/ARHP Annual Meeting
IL-6 Trans-Signalling Activates M2 Macrophage Polarisation and Mediates Fibrotic Response in Scleroderma
Rebecca Alade, Shiwen Xu, Korsa Khan, Angela Tam, Christopher P. Denton and Voon H. Ong, Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School Royal Free Campus, London, United Kingdom
Background/Purpose IL6 is a key mediator in activation of extracellular matrix (ECM) in scleroderma (SSc) fibroblasts and via its interplay with chemokines may modulate mononuclear…
Abstract Number: 2263 • 2013 ACR/ARHP Annual Meeting
ADAMTS5 Is a Biomarker For The Efficacy Prediction Of Tocilizumab In Rheumatoid Arthritis
Kensei Tsuzaka, Masako Takao and Jiro Nishida, Dept of Internal Medicine, Ichikawa General Hospital,TDC, Ichikawa, Chiba, Japan
a disintegrin and metalloproteinase with thrombospondin motifs 5 (ADAMTS5) mRNA level. In this study presented here, we investigated whether the efficacy of tocilizumab (TCZ) for…
Abstract Number: 558 • 2013 ACR/ARHP Annual Meeting
Fli-1 Regulates Immune Cell Infiltration Through Affecting Local Chemokine Expression and IL-6 Expression In The Kidney Of Lupus Prone Mice
Shuzo Sato¹, Sarah Williams², Eva Karam³ and Xian Zhang⁴, ¹Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, ²Ralph H. Johnson VA Medical Center, Charleston, SC, ³Medicine, Medical University of South Carolina, Charleston, SC, ⁴Medicine, Medical University of South Carolina and Ralph H. Johnson VA Medical Center, Charleston, SC
Background/Purpose: Fli-1 expression level, a member of the Ets family of transcription factors, is a mitigating factor in the development of nephritis in murine models…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].